US FDA rejects Pfizer rare neurodegenerative disease drug
This article was originally published in Scrip
Pfizer revealed on 18 June after the markets closed that it received a complete response letter (CRL) from the US FDA for the firm's new drug application (NDA) for Vyndaqel (tafamidis meglumine), which the company is seeking to market as a therapy for transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare, genetic progressive neurodegenerative disease, in which there is a buildup of amyloid, primarily in peripheral nerves, but also in the organs.
You may also be interested in...
Open-label extension Phase II data with RNAi candidate shows patients with transthyretin-mediated amyloidosis polyneuropathy may be regaining sensation and possibly even regenerating nerves.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.